MetLife Q4 2025 Earnings Call Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2026
0mins
Should l Buy MET?
Source: seekingalpha
- Strategic Progress: MetLife reported approximately $600 million in new adjusted premiums and revenues in 2025, reflecting a 10% year-over-year growth in its Group Benefits business, which strengthens its competitive position in a challenging market.
- Record Pension Risk Transfer Sales: The company achieved over $14 billion in pension risk transfer sales in 2025, marking significant growth in asset management, with year-end assets under management reaching $742 billion, highlighting strategic success in investment management.
- Shareholder Returns and Investments: MetLife returned about $2.9 billion to shareholders through stock repurchases and $1.5 billion in dividends in 2025, demonstrating its commitment to shareholder value while also investing approximately $1.2 billion in acquisitions and business development.
- Future Outlook and Targets: Management expects double-digit adjusted EPS growth in 2026, with adjusted ROE projected between 15% and 17%, indicating sustained growth potential and an enhanced market leadership position in the coming years.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MET?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MET
Wall Street analysts forecast MET stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 67.700
Low
84.00
Averages
95.25
High
108.00
Current: 67.700
Low
84.00
Averages
95.25
High
108.00
About MET
MetLife, Inc. is a financial services company, providing insurance, annuities, employee benefits and asset management to individual and institutional customers. Its segments include Group Benefits; Retirement and Income Solutions (RIS); Asia; Latin America; Europe, the Middle East and Africa (EMEA); and MetLife Holdings. Group Benefits segment offers life insurance, dental, group short- and long-term disability, paid family and medical leave, individual disability, accidental death and dismemberment insurance, accident and health insurance, and vision, as well as prepaid legal plans and pet insurance. RIS segment provides funding and financing solutions that help institutional customers mitigate and manage liabilities primarily associated with their employee benefit programs using a spectrum of life and annuity-based insurance and investment products. It operates across EMEA in both developed (Western Europe) and emerging (Central and Eastern Europe, Middle East and Africa) markets.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Rule Repeal Impact: The U.S. court has struck down the fiduciary rule aimed at enhancing retirement investor protections for the second time, which may lead to retirement investors receiving investment advice that does not serve their best interests, thereby increasing market confusion and uncertainty.
- Historical Repetition: This event mirrors the previous repeal of a similar rule during the Obama administration, highlighting the financial industry's resistance to regulatory measures through legal challenges, potentially exposing investors to lower protection standards.
- Investment Decision Risks: Recent data shows that approximately 6 million individuals rolled nearly $700 billion into IRAs in 2022, and the absence of fiduciary rules may diminish the quality of advice surrounding these significant financial decisions, increasing risks for investors.
- Industry Reaction: The insurance industry welcomed this ruling as a victory for consumers, arguing that the Biden-era rule exceeded the Department's authority, indicating that future investors must be more cautious in selecting advisors to ensure they receive transparent and interest-aligned advice.
See More
- Stock Performance: MetLife (MET) shares have declined by 11.7% year-to-date, underperforming the broader industry decline of 10.4%, indicating market caution regarding its future growth prospects.
- Valuation Appeal: With a market capitalization of approximately $45.9 billion, the stock trades at a forward P/E ratio of 6.9X, significantly below the industry average of 8.3X, suggesting potential undervaluation that may attract value investors.
- Revenue Growth Expectations: The consensus estimate for 2026 earnings is pegged at $9.85 per share, indicating an 11.6% year-over-year increase, and despite two downward revisions in the past 30 days, it still reflects potential improvement in the company's profitability.
- Strategic Expansion: Through acquisitions of Versant Health, PetFirst, and PineBridge Investments, MetLife is enhancing its capabilities in benefits, asset management, and annuities, further driving long-term growth potential.
See More
- Valuation Advantage: As of March 24, S&P 500 financial stocks have a forward P/E of 14, ranking in the 29th percentile of absolute P/E over the past decade, indicating relative cheapness in a high-valuation market, thus attracting investor interest.
- Interest Rate Outlook: The onset of the Iran war may lead the Federal Reserve to consider rate hikes before the end of 2026, which would directly boost net interest income for financial stocks, particularly for companies like Wells Fargo and MetLife.
- Market Dynamics Shift: With inflation expectations rising from 2.4% to 3.16%, the low P/E ratios of financial stocks may draw more investors, especially given the overall high valuations in the current market, making the financial sector's performance particularly significant.
- Investment Opportunities: Within the S&P 500, 30 financial stocks have forward P/E ratios below 10, with Wells Fargo and MetLife at 10 and 6.4 respectively, representing discounts of 10% and 23% to their average forward P/E ratios over the last five years, providing significant value opportunities for investors.
See More
- Valuation Advantage: The current P/E ratio of 14 for S&P 500 financial stocks ranks in the 29th percentile over the past decade, highlighting their relative cheapness in an otherwise expensive market, thus attracting investor interest.
- Changing Rate Outlook: The outbreak of the Iran war has shifted market expectations for interest rates, with the Federal Reserve potentially enacting rate hikes before the end of 2026, which would benefit financial stocks through increased net interest income.
- Key Financial Stocks: Among the 70 financial stocks in the S&P 500, 30 ended the March 24 trading session with a forward P/E ratio below 10, including Wells Fargo and MetLife, which show respective forward P/E ratios of 10 and 6.4, representing discounts that appeal to value investors.
- Market Environment Impact: Although financial stocks are typically highly cyclical, the current low P/E ratios combined with the potential for rising interest rates provide investors with opportunities to find value in a historically expensive market, potentially driving a recovery in the sector.
See More
- New Appointment: MetLife announced that Jordan Canter will join as head of Federal Government Affairs and Regulatory Policy effective April 20, overseeing the company's federal government affairs and global regulatory policy to support business priorities through collaboration with stakeholders.
- Extensive Experience: Canter comes from Allstate, where she held senior roles managing federal government affairs and public policy, leading initiatives across a wide range of financial services and insurance matters, showcasing her deep expertise in public policy and regulatory issues.
- Strategic Importance: As the policy and regulatory landscape becomes increasingly complex, Canter's appointment is seen as a crucial move to enhance MetLife's influence with federal policymakers and regulators, aimed at advancing the company's priorities.
- Educational Background: Canter holds a bachelor's degree from Franklin & Marshall College, and her expertise in government affairs and regulatory policy is expected to support MetLife's future growth.
See More
- Acquisition Proposal Overview: On March 10, MetLife Inc. (NYSE:MET) confirmed it received an unsolicited mini-tender offer from Potemkin to purchase 10,000 shares of its common stock, representing approximately 0.002% of MetLife's total outstanding shares as of February 12.
- Price Discrepancy Analysis: As of March 9, MetLife's common stock closed at $70.77, which is nearly 27.09% higher than Potemkin's offer of $51.60 per share, highlighting a significant market value disparity.
- Company Position Statement: Given that Potemkin's offer price is below the current market price, MetLife has clearly stated it does not support the offer and advises shareholders against taking any action regarding it to protect their interests.
- Analyst Rating Update: On February 25, Wells Fargo analyst Elyse Greenspan lowered MetLife's price target from $97 to $93, still indicating a potential upside of nearly 35% at the prevailing level, while maintaining an Overweight rating on the stock.
See More











